| Literature DB >> 29262638 |
Huan Tuo1, Feng Shu1, Sha She1, Min Yang1, Xiao Qin Zou1, Juan Huang1, Huai Dong Hu1,2, Peng Hu1,2,3, Hong Ren1,2,3, Shi Fang Peng4,5, Yi Xuan Yang1,2,3.
Abstract
Gastric cancer (GC) is a globally occurring malignancy that is characterized by a high mortality rate due to a high tendency to metastasize and poor prognoses. Sorcin, as known as SRI, a soluble resistance-related calcium-binding protein, plays a significant role in multidrug resistance. Sorcin is related to the migration and invasion of cancer cells. However, the mechanism remains unclear. Here, we used immunohistochemistry to confirm that the expression of sorcin in cancer tissues is higher than that in the adjacent normal tissues. The wound healing and transwell results indicate that sorcin can induce migration and invasion of GC cells. To explore the role of sorcin in GC metastasis, isobaric tags for relative and absolutely quantitation (iTRAQ) were used to examine cells with and without sorcin knockdown to identify the differentially expressed proteins (DEPs). The results were evaluated via RT-PCR and western blot to confirm the ITRAQ data. Inhibition of sorcin expression can down- regulate the expression of CTSZ, MMP2, MMP9 and p-STAT3 followed by suppression of tumor growth and metastasis. Together, we concluded that sorcin has a oncogenic activity via inducing tumor growth and metastasis, leading to development of therapeutic treatments for GC.Entities:
Keywords: gastric cancer (GC); iTRAQ; invasion; migration; sorcin
Year: 2017 PMID: 29262638 PMCID: PMC5732804 DOI: 10.18632/oncotarget.22208
Source DB: PubMed Journal: Oncotarget ISSN: 1949-2553
Figure 1Sorcin levels were higher in GC tissue than in adjacent normal tissue
(A) Representative images of the immmunohistochemical analysis of Sorcin in GC tissue and matched GC adjacent normal tissue. (B) IHC score values of Sorcin are significantly higher in GC tissue compared to matched GC adjacent normal tissue. * P<0.001.
Pearson correlation coefficients between IHC scoring, tumor grade, and tumor stage
| 1 | 2 | 3 | |
|---|---|---|---|
| 1 IHC scoring | 1 | ||
| 2 Grade | 0.817** | 1 | |
| 3 Stage | 0.869** | 0.92** | 1 |
* P < 0.05 ** P < 0.01 *** P < 0.001.
Figure 2(A) Western blot analysis showed that three different siRNAs targeting sorcin specific siRNAs significantly reduced SRI protein levels in cell lysates, compared to control siRNA and lipo2000 and band intensity analysis. (B) Migration ability of cells in wound healing assays after sorcin knockdown. * P<0.05., Migration ability of AGS and MKN28 after silencing SRI. (C) Invasion ability of AGS and MKN28 after silencing SRI.
The iTRAQ-based MS workflow
The proteins observed to be differentially expressed by iTRAQ analysis in supernatant of AGS and MKN28: SRI knockdown vs control
| AGS | ||||||
|---|---|---|---|---|---|---|
| N | Accession | Name | 114:113 | PVal 114:113 | 116:115 | PVal 116:115 |
| 1 | sp|Q9NPD8|UBE2T_HUMAN | Ubiquitin-conjugating enzyme E2 T | 1.744066 | 0.026624629 | 1.325548983 | 0.044529971 |
| 2 | tr|H6VRG1|H6VRG1_HUMAN | Keratin 1 | 1.523257017 | 0.001 | 1.7892345 | 0.02378564 |
| 3 | sp|Q14019|COTL1_HUMAN | Coactosin-like protein | 1.486366034 | 0.003839253 | 1.9871653 | 0.00457829 |
| 4 | sp|P02787|TRFE_HUMAN | Serotransferrin | 1.47558701 | 0.001567603 | 1.79888654 | 0.00167298 |
| 5 | sp|P35527|K1C9_HUMAN | Keratin, type I cytoskeletal 9 | 1.456223011 | 0.000636358 | 1.89176432 | 0.000398717 |
| 6 | tr|D3DPK5|D3DPK5_HUMAN | SH3 domain binding glutamic protein like 3 | 1.416821957 | 0.01751755 | 1.56279981 | 0.0192865 |
| 7 | sp|P60174|TPIS_HUMAN | Triosephosphate isomerase | 1.394827962 | 0.000135839 | 1.52817629 | 0.000027817 |
| 8 | sp|P62195|PRS8_HUMAN | 26S protease regulatory subunit 8 | 1.392753959 | 0.0281204 | 1.79875428 | 0.0367186 |
| 9 | sp|Q5JS37|NHLC3_HUMAN | NHL repeat-containing protein 3 | 1.388023019 | 0.045731839 | 1.591827113 | 0.0378192 |
| 10 | tr|Q53FB6|Q53FB6_HUMAN | Mitochondrial aldehyde dehydrogenase 2 variant | 1.377797961 | 0.000768409 | 1.398271918 | 0.00036182 |
| 11 | sp|P04075|ALDOA_HUMAN | Fructose-bisphosphate aldolase A | 1.372123957 | 0.00147034 | 1.679281179 | 0.0017891 |
| 12 | sp|Q5T4S7|UBR4_HUMAN | E3 ubiquitin-protein ligase UBR4 | 1.350811958 | 0.03672374 | 1.378291179 | 0.028917123 |
| 13 | tr|Q6FGB3|Q6FGB3_HUMAN | PCBD protein (Fragment) | 1.343956947 | 0.01979435 | 1.562919023 | 0.018273689 |
| 14 | sp|Q9Y3C6|PPIL1_HUMAN | Peptidyl-prolyl cis-trans isomerase-like 1 | 1.343673944 | 0.01674393 | 1.782993739 | 0.017289381 |
| 15 | tr|Q5U000|Q5U000_HUMAN | Cathepsin Z | 0.749955177 | 0.035744209 | 0.65124789 | 0.02134678 |
| 16 | sp|P02647|APOA1_HUMAN | Apolipoprotein A-I | 0.746485889 | 0.01251418 | 0.635172839 | 0.013671898 |
| 17 | tr|B4DVA7|B4DVA7_HUMAN | Beta-hexosaminidase | 0.725379229 | 0.002918514 | 0.726019284 | 0.002189322 |
| 18 | sp|Q0VDF9|HSP7E_HUMAN | Heat shock 70 kDa protein 14 | 0.725047827 | 0.037717941 | 0.6218956 | 0.031275433 |
| 19 | sp|P18065|IBP2_HUMAN | Insulin-like growth factor-binding protein 2 | 0.718883276 | 0.007395078 | 0.71452389 | 0.001789562 |
| 20 | tr|G3V1C3|G3V1C3_HUMAN | Apoptosis inhibitor 5 | 0.709504426 | 0.000174285 | 0.7219271 | 0.000342613 |
| 21 | tr|Q6IBU0|Q6IBU0_HUMAN | EIF5 protein | 0.707335413 | 0.02353386 | 0.682615293 | 0.03782919 |
| 22 | sp|Q14393|GAS6_HUMAN | Growth arrest-specific protein 6 | 0.705515504 | 0.037340712 | 0.67281927 | 0.000128913 |
| 23 | sp|Q96JB5|CK5P3_HUMAN | CDK5 regulatory subunit-associated protein 3 | 0.704363883 | 0.04963446 | 0.672918274 | 0.038291833 |
| 24 | sp|P31949|S10AB_HUMAN | Protein S100-A11 | 0.67395997 | 0.033712041 | 0.631987527 | 0.02567891 |
| 25 | sp|P23396|RS3_HUMAN | 40S ribosomal protein S3 | 0.662013173 | 0.000471662 | 0.452719272 | 0.000261839 |
| 26 | sp|Q9NZL4|HPBP1_HUMAN | Hsp70-binding protein 1 | 0.600465178 | 0.000367309 | 0.52918762 | 0.000271836 |
| 27 | sp|P01037|CYTN_HUMAN | Cystatin-SN | 0.576057613 | 0.001708777 | 0.342516829 | 0.001728391 |
| 28 | sp|Q9H173|SIL1_HUMAN | Nucleotide exchange factor SIL1 | 0.574737787 | 0.0174674 | 0.328910722 | 0.001729372 |
| 29 | sp|P21926|CD9_HUMAN | CD9 antigen | 0.516185224 | 0.020510839 | 0.035617839 | 0.025618923 |
| 30 | sp|P04080|CYTB_HUMAN | Cystatin-B | 0.473518968 | 0.003953285 | 0.49178256 | 0.000267819 |
Figure 3PANTHER analysis of proteins differentially expressed in GC cells
(A) AGS Proteins were categorized by protein class, biological process, and molecular function. (B) MKN28 Proteins were categorized by protein class, biological process, and molecular function. (C) STRING analysis.
Figure 4Validation of differentially expressed proteins in mRNA level
RT-PCR detected the relative mRNA expression levels of some DEPs in the sorcin knockdown group compared with untreated (no knockdown) group.
Figure 5Validation of differentially expressed proteins in protein level
Western blot analysis of CTSZ, HSPBP1, STAT3, p-STAT3, MMP9 and MMP2. (A) Protein levels from AGS cells transfected with SRI-specific or control siRNAs were analyzed by western blot analysis. Band intensity analysis shows significant reduction of p-STAT3, MMP9, and MMP2 after sorcin silencing (* P<0.05). (B) Protein levels from MKN28 cells transfected with SRI-specific or control siRNAs were analyzed by western blot analysis. Band intensity analysis shows significant reduction of p-STAT3, MMP9, and MMP2 after sorcin silencing (* P<0.05).
Figure 6GC proliferation after knockdown of SRI
(A) Proliferation was significant inhibit in cell transfected with SRI- specific siRNA in AGS (* P<0.05). (B) Proliferation was significant inhibit in cell transfected with SRI- specific siRNA in MKN28 (* P<0.05).
The sequence of genes specific primers as followed
| Gene | Primer sequence | Gene | Primer sequence |
|---|---|---|---|
| UBE2T | F 5-TGCGAGCTCGTAGAAATATT-3 | CTSZ | F 5-CGGCCTCATGAGTACCTGTC-3 |
| R 5-TTGAGGGATGGTCTCCAAGC-3 | R 5-GCAGTATTGGGGGATGTGCT-3 | ||
| HSPBP1 | F 5-CCTCTTCGCCATCTCCTGTC-3 | S100A11 | F 5-CTATGGCTTGCCATGACTCCT-3 |
| R 5-TCAACACAGAGAAGCCGTCC-3 | R 5-TACAAGAAAGTTGGGCAGGTCC-3 | ||
| CSTB | F 5-TCCCTGTGTTTAAGGCCGTG-3 | MMP1 | F 5-GCGAGCCCTCCTTTATCTCC-3 |
| R 5-ACACTCGCAGGTGTACGAAG-3 | R 5-AGGGTCTAAAACGCCAGTCG-3 | ||
| RAC1 | F 5-AGGCAAACGCCCATTGGATA-3 | KRT1 | F 5-GGTGTCAAGTCCTCTGGTGG-3 |
| R 5-ACTGCGGTCACTTACCTTGG-3 | R 5-ACAAGAAAGTTGGGTATCTGGT-3 | ||
| TIMP2 | F 5-TCAAGAGAAGTGACGGCTCC-3 | VEGFA | F 5-TGCGGATCAAACCTCACCAA-3 |
| R 5-ACAAGAAAGTTGGGTATGGGTCC-3 | R 5-CAAGAAAGTATGGGCACCGC-3 | ||
| IBP4 | F 5-CAAGTGCTGGTGTGTGGACC-3 | ||
| R 5-AAGAAAGTTGGGCACTCTCGAA-3 |